Science and Research

COAST: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

A study of OPT-302 with aflibercept in neovascular age-related macular degeneration (nAMD) (COAST).


A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.

Primary efficacy will be determined at Week 52.

For further information about this study please contact the Clinical Trials Research Centre on (03) 99298076 or email trials@cera.org.au.

  • Principal Investigator
Dr Thanh Nguyen

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.